Pre-market
Loading markets…
Stocks/NASDAQ/KTTA

Pasithea Therapeutics Corp (KTTA : NASDAQ)

Common Stock

$0.53

USD

+0.16 (44.02%)

Last updated: 2026-11-03

Follow KTTA

KTTA

Pasithea Therapeutics Corp

Source:WealthAwesomeWealthAwesome
↑ $0.02 (3.37%)
30 day period
$0.37$0.45$0.53Sep 23Oct 14Nov 3

Performance

1 Day

+44.02%

1 Week

+33.40%

1 Month

+11.34%

YTD

+5.58%

Key Statistics

Market Cap

$12.30M

52W High

$2.06

52W Low

$0.28

P/E Ratio

-

50 Day MA

$0.49

200 Day MA

$0.63

Beta

0.44

Dividend Yield

-

Technical Indicators

Price vs 50-Day SMA

↑Above 50 SMA

Price vs 200-Day SMA

↓Below 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
11/3/2026$0.36$0.53$0.35$0.53$0.5321,182,181
11/2/2026$0.38$0.40$0.35$0.37$0.37247,547
10/30/2026$0.36$0.39$0.36$0.37$0.3799,800
10/29/2026$0.38$0.41$0.35$0.37$0.37329,714
10/28/2026$0.39$0.40$0.37$0.39$0.39596,524
10/27/2026$0.40$0.42$0.37$0.40$0.40649,129
10/26/2026$0.40$0.41$0.37$0.40$0.40628,873
10/23/2026$0.45$0.47$0.34$0.41$0.411,533,400
10/22/2026$0.49$0.50$0.45$0.45$0.45378,794
10/21/2026$0.42$0.50$0.42$0.49$0.49774,923

Analyst Price Targets

Based on 1 analyst covering KTTA · as of Sep 17, 2026

📈

Wall Street analysts forecast KTTA stock price to rise 466.0% over the next 12 months.

Consensus

Strong Buy

5.00 / 5.00

Avg. Target

US$3.00

+466.0% Upside

Current Price

US$0.53

Last close

Analyst Breakdown (1 analysts)

Strong Buy 1
Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on KTTA's historical volatility

HistoricalForecast68%95%
US$0.13US$0.73US$1.33US$1.93US$2.53US$3.14TodayJun 29Sep 1Nov 3Dec 16Jan 29Mar 13

30-Day Vol

132.3%

Annualized

90-Day Vol

93.9%

Annualized

Trend (90d)

+46.9%

Annualized drift

90d Mean

US$0.63

Expected price

HorizonExpected68% Range (1σ)
30 trading daysUS$0.56US$0.36 – US$0.88
60 trading daysUS$0.59US$0.31 – US$1.13
90 trading daysUS$0.63US$0.28 – US$1.38

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Pasithea Therapeutics Corp

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Financials

Revenue (TTM)
$486,559
EBITDA
$-19.14M
Profit Margin
0.00%
ROE (TTM)
-65.49%
EPS (Diluted)
-1.59
Book Value
1.49

Classification

Sector
Health Care
Industry
Biotechnology
Group
Pharmaceuticals, Biotechnology & Life Sciences

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report

Common Questions About KTTA.US

Market movers

Recent NASDAQ movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
CHSNChanson International Holding Class A Ordinary Shares$3.38+241.24%
RDACRising Dragon Acquisition Corp. Ordinary Shares$11.30+121.57%
MERCMercer International Inc$0.21+68.25%
PARAParabolic Technologies, Inc.$2.72+60.95%
FEEDENvue Medical Inc.$0.35+40.00%
IFBDInfobird Co Ltd$1.43+38.83%
CRMTAmericas Car-Mart Inc$1.21+32.73%
EHGOEshallgo Inc.$2.50+30.89%